CompletedPhase 1NCT06063330

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Red Queen Therapeutics, Inc.
Principal Investigator
Paul Eisenberg, MD, MPH
Red Queen Therapeutics
Intervention
RQ-001(combination_product)
Enrollment
66 target
Eligibility
18-64 years · All sexes
Timeline
20232024

Study locations (6)

Collaborators

PPD Development, LP

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06063330 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials